Search Articles

View query in Help articles search

Search Results (1 to 1 of 1 Results)

Download search results: CSV END BibTex RIS


Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

The difference was 17.9% (95% CI -2 to 37.7; P=.08). Subjects (n=69) at the 21 US sites not participating in the AI substudy had cumulative pharmacokinetic adherence over 24 weeks of 78.1% (SD 29.7). The analysis set consisted of all subjects who received any dose of ABT-126 at US sites selected to use the AI Platform and who had available pharmacokinetic data. Visits were based on a categorization of collection day data into weekly windows.

Earle E Ellen Bain, Laura Shafner, David P Walling, Ahmed A Othman, Christy Chuang-Stein, John Hinkle, Adam Hanina

JMIR Mhealth Uhealth 2017;5(2):e18

Cookie Consent

We use our own cookies and third-party cookies so that we can show you this website and better understand how you use it, with a view to improving the services we offer. If you continue browsing, we consider that you have accepted the cookies.